

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Brilliant Violet 711(TM) anti-human CD8

RRID:AB_2565242

Type: Antibody

Proper Citation

BioLegend Cat# 344733, RRID:AB_2565242

Antibody Information

URL: http://antibodyregistry.org/AB_2565242

Proper Citation: BioLegend Cat# 344733, RRID:AB_2565242

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2565242

Vendor: BioLegend

Catalog Number: 344733

Alternative Catalog Numbers: 344734

Record Creation Time: 20250820T061054+0000

Record Last Update: 20250820T232847+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 711(TM) anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Powers JS, et al. (2026) Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies. Cell reports. Medicine, 7(3), 102636.

Lin Y, et al. (2026) Regulatory T cell-derived TGF- γ signaling governs the differentiation and maintenance of tumor-infiltrating bystander CD8+ T cells. Cell reports, 45(4), 117189.

Bui TM, et al. (2026) Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. Cancer cell, 44(6), 1179.

Chauhan SK, et al. (2024) Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation. NPJ breast cancer, 10(1), 30.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell reports, 41(3), 111478.